AR074297A1 - Combinacion farmaceutica sinergica que comprende un atagonista del receptor de estrogeno y una progestina - Google Patents

Combinacion farmaceutica sinergica que comprende un atagonista del receptor de estrogeno y una progestina

Info

Publication number
AR074297A1
AR074297A1 ARP090104296A ARP090104296A AR074297A1 AR 074297 A1 AR074297 A1 AR 074297A1 AR P090104296 A ARP090104296 A AR P090104296A AR P090104296 A ARP090104296 A AR P090104296A AR 074297 A1 AR074297 A1 AR 074297A1
Authority
AR
Argentina
Prior art keywords
acetate
org
beta
pharmaceutical combination
7alpha
Prior art date
Application number
ARP090104296A
Other languages
English (en)
Inventor
Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR074297A1 publication Critical patent/AR074297A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Coadministración de un antagonista del receptor de estrógeno y una progestina para tratar enfermedades ginecológicas que son el resultado del crecimiento anormal del tejido del útero, tales como, la endometriosis o los fibroides uterinos. Reivindicación 4: Combinación farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el antagonista del receptor de estrógeno es fulvestrant, raloxifeno, tamoxifeno, toremifeno, arzoxifeno, CHF-4227, lasofoxifeno, LY-2066943, LY-2120310, ospemifeno, sivifeno, TAS-108, bazedoxifeno o acetato de bazedoxifeno, afimoxifeno, enclomifeno, fispemifeno, acolbifeno, EM-652, droloxifeno, GW-7603, centcromano, levormeloxifeno, ICI-164384, A-007, PSK-3471, BL-3040, CH-4893237, SRI-16158, SRI 16137, Rad-1901, 11beta-fluoro-7alfa-[5-(metil3-[(4,4,5,5,5-pentafluoropentil}sulfanil]propilamino)gentil]estra-1,3,5(10)-trien-3,17beta-diol, 11beta-fluoro-17alfa-metil-7alfa-5-[metil(8,8,9,9,9,9-pentafluorononil)amino]pentilestra-1,3,5(10)-trien-3,17beta-diol o (+)-3-(4-hidroxifenil)-2- [4-(2-piperidin-1-iletoxi) fenil]-4-(trifluorometil)-2H-cromen-7-ol. Reivindicación 5: Combinación farmacéutica de acuerdo con la reivindicación 1, caracterizada porque la progestina es desogestrel, dienogest, drospirenona, gestodeno, levonorgestrel, medroxiprogesterona, acetato de medroxiprogesterona, acetato de megestrol, nomegestrol, acetato de noretindrona, noretinodrel, noretisterona, acetato de noretisterona, norgestimato, norgestrel, NorLevo, progesterona, SH-329, SH-461, SH-543, tibolona, trimegestona, ciproterona, nestorona, acetato de nomegestrol, Org-201745, Org-42669, Org-47241, Org-32818, tanaproget, AP-1081, ETI-411, FPMA, NSP-808, eltanolona, etonorgestrel, tosagestina o TX-525.
ARP090104296A 2008-11-11 2009-11-06 Combinacion farmaceutica sinergica que comprende un atagonista del receptor de estrogeno y una progestina AR074297A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008057230A DE102008057230A1 (de) 2008-11-11 2008-11-11 Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin

Publications (1)

Publication Number Publication Date
AR074297A1 true AR074297A1 (es) 2011-01-05

Family

ID=41606625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104296A AR074297A1 (es) 2008-11-11 2009-11-06 Combinacion farmaceutica sinergica que comprende un atagonista del receptor de estrogeno y una progestina

Country Status (6)

Country Link
AR (1) AR074297A1 (es)
DE (1) DE102008057230A1 (es)
PA (1) PA8847901A1 (es)
TW (1) TW201022251A (es)
UY (1) UY32235A (es)
WO (1) WO2010054758A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
WO2013131105A1 (en) * 2012-03-02 2013-09-06 Sri International Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
CN104370796B (zh) * 2014-11-21 2016-09-14 扬子江药业集团有限公司 一种醋酸巴多昔芬多晶型b的制备方法
KR20180059427A (ko) 2015-07-14 2018-06-04 노벨파마 컴퍼니 리미티드 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
WO2003063859A1 (en) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
JP4656939B2 (ja) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen

Also Published As

Publication number Publication date
TW201022251A (en) 2010-06-16
UY32235A (es) 2010-06-30
WO2010054758A1 (en) 2010-05-20
PA8847901A1 (es) 2010-06-28
DE102008057230A1 (de) 2010-05-12

Similar Documents

Publication Publication Date Title
AR074297A1 (es) Combinacion farmaceutica sinergica que comprende un atagonista del receptor de estrogeno y una progestina
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BR112012014059A2 (pt) gel transdérmico de progestina / estradiol.
MX347890B (es) Neuroproteccion y reparacion de melina usando progestina.
DOP2012000015A (es) (11ß,17ß)–17–HIDROXI–11–[4–(METILSULFONIL)FENIL]–17–(PENTAFLUOROETIL)ESTRA–4,9–DIEN–3–ONA CON ACCIÓN ANTAGONISTA EN EL RECEPTOR DE PROGESTERONA
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
RU2011149223A (ru) Внутриматочная система для лечебного использования
CA2369077A1 (en) Contraceptive compositions containing quinazolinone and benzoxazine derivatives
RS89504A (en) 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
NZ597583A (en) Treatment of alzheimer’s disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
JP2011518883A5 (es)
JP2014532685A (ja) １８−メチル−６，７−メチレン−３−オキソ−１７−プレグナ−４−エン−２１，１７β−カルボラクトン、該化合物を含有する医薬製剤、および子宮内膜症の治療におけるその使用
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
WO2009138186A3 (de) SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN
AR121864A1 (es) Composiciones anticonceptivas con efectos adversos reducidos
CZ299942B6 (cs) Farmaceutické prostredky obsahující antiprogestinpro prevenci a lécení hormonálne závislých onemocnení
PE20070182A1 (es) Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
TN2015000454A1 (en) Progesterone receptor antagonist dosage form
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
MA32477B1 (fr) Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique
Wilkens et al. Progesterone receptor modulators in gynaecological practice
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest

Legal Events

Date Code Title Description
FB Suspension of granting procedure